AfricaRegulatory
African Pharmaceutical Regulatory Intelligence
Acalabrutinib
5 registrations across 3 African markets— 5 active
Markets with Acalabrutinib
Recent registrations
| Brand / Product | Market | Holder | Status | Expires |
|---|---|---|---|---|
| Acalabrutinib Film-coated tablets, | 🇷🇼Rwanda | AstraZeneca AB | active | Feb 2031 |
| ACALABRUTINIB CIPLA | 🇿🇦South Africa | Cipla Medpro (Pty) Ltd | active | Jul 2028 |
| GENCALQ | 🇿🇦South Africa | Cipla Medpro (Pty) Ltd | active | Jul 2028 |
| CALQUENCE | 🇿🇦South Africa | AstraZeneca Pharmaceuticals (Pty) Ltd | active | Mar 2027 |
| CALQUENCE Film coated tablets | 🇹🇿Tanzania | AstraZeneca UK Limited | active | — |
Acalabrutinib in Africa — Regulatory Overview
Acalabrutinib is registered across 3 African markets with 5 total product registrations on file. Data is sourced directly from official national drug regulatory authorities including South Africa, Rwanda, Tanzania. AfricaRegulatory refreshes this data daily from official government sources.
Of the 5 registrations, 5 (100%) are currently active. Regulatory affairs teams use AfricaRegulatory to track registration expiry dates, identify market incumbents, and monitor approval status across African markets without manual monitoring of each national regulator.